Background: The aim was to optimize antigen challenge for induction of airway hyperresponsiveness (AHR) and inflammation in BALB/c mice sensitized to ovalbumin (OVA). Comparisons were made between mice challenged with OVA either as an aerosol or intranasally. The protocol that induced maximal AHR in BALB/c mice was thereafter tested in C57BL/6 mice. Method: Methacholine responsiveness was measured using the flexiVent® system to assess AHR. Inflammatory responses were investigated by histology and cell counts in bronchoalveolar lavage (BAL) fluid. Results: 48 h after challenge with 1 or 6% OVA aerosols, there were similar increments in AHR and BAL cells, predominantly eosinophils. When comparing the effect of 1% OVA aerosol on AHR and cell infiltration at 24 and 48 h after challenge, the responses were similar. At 24 h, intranasal OVA administration (20–200 µg) caused a dose-dependent increase in AHR. BAL cells were increased by all intranasal OVA doses and to a greater extent than after 1% OVA aerosol challenge but without any dose dependency. Histological examination confirmed that there was an increase of eosinophils in lung tissue following either challenge. In C57BL/6 mice, baseline tissue elastance was the only functional outcome that was increased after intranasal OVA challenge. Even though the AHR response was negligible in C57BL/6 mice, a similar infiltration of BAL cells was observed in both strains. Conclusion: Intranasal challenge was more effective than aerosol challenge at inducing both AHR and airway inflammation in BALB/c mice. Although intranasal challenge caused airway inflammation in C57BL/6 mice, this strain is not optimal for studying AHR.

Keywords:
Airway responsiveness, Challenge, Mouse strain, Protocol optimization, Sensitization
1.
Nials AT, Uddin S: Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech 2008;1:213–220.
2.
Zhang Y, Lamm WJ, Albert RK, Chi EY, Henderson WR Jr, Lewis DB: Influence of the route of allergen administration and genetic background on the murine allergic pulmonary response. Am J Respir Crit Care Med 1997;155:661–669.
3.
Chang YS, Kim YK, Bahn JW, Kim SH, Park HW, Kim TB, Cho SH, Min KU, Kim YY: Comparison of asthma phenotypes using different sensitizing protocols in mice. Korean J Intern Med 2005;20:152–158.
4.
Nelde A, Teufel M, Hahn C, Duschl A, Sebald W, Brocker EB, Grunewald SM: The impact of the route and frequency of antigen exposure on the IgE response in allergy. Int Arch Allergy Immunol 2001;124:461–469.
5.
Whitehead GS, Walker JK, Berman KG, Foster WM, Schwartz DA: Allergen-induced airway disease is mouse strain dependent. Am J Physiol 2003;285:L32–L42.
6.
Brewer JP, Kisselgof AB, Martin TR: Genetic variability in pulmonary physiological, cellular, and antibody responses to antigen in mice. Am J Respir Crit Care Med 1999;160:1150–1156.
7.
Swedin L, Neimert-Andersson T, Hjoberg J, Jonasson S, van Hage M, Adner M, Ryrfeldt A, Dahlen SE: Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J 2009;34:200–208.
8.
Jonasson S, Swedin L, Lundqvist M, Hedenstierna G, Dahlen SE, Hjoberg J: Different effects of deep inspirations on central and peripheral airways in healthy and allergen-challenged mice. Respir Res 2008;9:23.
9.
Barnas GM, Ho G, Green MD, Harinath P, Smalley AJ, Campbell DN, Mendham JE: Effects of analysis method and forcing waveform on measurement of respiratory mechanics. Respir Physiol 1992;89:273–285.
10.
Tomioka S, Bates JH, Irvin CG: Airway and tissue mechanics in a murine model of asthma: alveolar capsule vs forced oscillations. J Appl Physiol 2002;93:263–270.
11.
Hjoberg J, Shore S, Kobzik L, Okinaga S, Hallock A, Vallone J, Subramaniam V, De Sanctis GT, Elias JA, Drazen JM, Silverman ES: Expression of nitric oxide synthase-2 in the lungs decreases airway resistance and responsiveness. J Appl Physiol 2004;97:249–259.
12.
Hantos Z, Daroczy B, Suki B, Nagy S, Fredberg JJ: Input impedance and peripheral inhomogeneity of dog lungs. J Appl Physiol 1992;72:168–178.
13.
Irvin CG, Bates JH: Measuring the lung function in the mouse: the challenge of size. Respir Res 2003;4:4.
14.
Bates JH, Irvin CG: Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol 2003;94:1297–1306.
15.
Bates JH, Lutchen KR: The interface between measurement and modeling of peripheral lung mechanics. Respir Physiol Neurobiol 2005;148:153–164.
16.
Ellis R, Leigh R, Southam D, O’Byrne PM, Inman MD: Morphometric analysis of mouse airways after chronic allergen challenge. Lab Invest 2003;83:1285–1291.
17.
Leigh R, Ellis R, Wattie J, Southam DS, De Hoogh M, Gauldie J, O’Byrne PM, Inman MD: Dysfunction and remodelling of the mouse airway persist after resolution of acute allergen-induced airway inflammation. Am J Respir Cell Mol Biol 2002;27:526–535.
18.
Leigh R, Ellis R, Wattie JN, Hirota JA, Matthaei KI, Foster PS, O’Byrne PM, Inman MD: Type 2 cytokines in the pathogenesis of sustained airway dysfunction and airway remodeling in mice. Am J Respir Crit Care Med 2004;169:860–867.
19.
Leigh R, Southam DS, Ellis R, Wattie JN, Sehmi R, Wan Y, Inman MD: T-cell-mediated inflammation does not contribute to the maintenance of airway dysfunction in mice. J Appl Physiol 2004;97:2258–2265.
20.
Southam DS, Ellis R, Wattie J, Inman MD: Components of airway hyperresponsiveness and their associations with inflammation and remodeling in mice. J Allergy Clin Immunol 2007;119:848–854.
21.
Inman MD, Ellis R, Wattie J, Denburg JA, O’Byrne PM: Allergen-induced increase in airway responsiveness, airway eosinophilia, and bone-marrow eosinophil progenitors in mice. Am J Respir Cell Mol Biol 1999;21:473–479.
22.
Boost KA, Flondor M, Hofstetter C, Platacis I, Stegewerth K, Hoegl S, Nguyen T, Muhl H, Zwissler B: The β-adrenoceptor antagonist propranolol counteracts anti-inflammatory effects of isoflurane in rat endotoxemia. Acta Anaesthesiol Scand 2007;51:900–908.
23.
Reutershan J, Chang D, Hayes JK, Ley K: Protective effects of isoflurane pretreatment in endotoxin-induced lung injury. Anesthesiology 2006;104:511–517.
24.
Williams CM, Galli SJ: Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 2000;192:455–462.
25.
Zhu W, Gilmour MI: Comparison of allergic lung disease in three mouse strains after systemic or mucosal sensitization with ovalbumin antigen. Immunogenetics 2009;61:199–207.
26.
Yu M, Tsai M, Tam SY, Jones C, Zehnder J, Galli SJ: Mast cells can promote the development of multiple features of chronic asthma in mice. J Clin Invest 2006;116:1633–1641.
27.
Wagers SS, Haverkamp HC, Bates JH, Norton RJ, Thompson-Figueroa JA, Sullivan MJ, Irvin CG: Intrinsic and antigen-induced airway hyperresponsiveness are the result of diverse physiological mechanisms. J Appl Physiol 2007;102:221–230.
28.
Takeda K, Haczku A, Lee JJ, Irvin CG, Gelfand EW: Strain dependence of airway hyperresponsiveness reflects differences in eosinophil localization in the lung. Am J Physiol 2001;281:L394–L402.
29.
Gueders MM, Paulissen G, Crahay C, Quesada-Calvo F, Hacha J, Van Hove C, Tournoy K, Louis R, Foidart JM, Noel A, Cataldo DD: Mouse models of asthma: a comparison between C57BL/6 and BALB/c strains regarding bronchial responsiveness, inflammation, and cytokine production. Inflamm Res 2009;58:845–854.
30.
Jonasson S, Hedenstierna G, Hedenstrom H, Hjoberg J: Comparisons of effects of intravenous and inhaled methacholine on airway physiology in a murine asthma model. Respir Physiol Neurobiol 2009;165:229–236.
31.
Zosky GR, Larcombe AN, White OJ, Burchell JT, von Garnier C, Holt PG, Turner DJ, Wikstrom ME, Sly PD, Stumbles PA: Airway hyperresponsiveness is associated with activated CD4+ T cells in the airways. Am J Physiol 2009;297:L373–L379.
32.
Van Hove CL, Maes T, Cataldo DD, Gueders MM, Palmans E, Joos GF, Tournoy KG: Comparison of acute inflammatory and chronic structural asthma-like responses between C57BL/6 and BALB/c mice. Int Arch Allergy Immunol 2009;149:195–207.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.